GSK announces drug price deal with US government
I'm PortAI, I can summarize articles.
GSK PLC, a London-based pharmaceutical company, has announced an agreement with the US government to reduce prescription medicine costs for American patients, focusing on respiratory conditions like asthma and COPD. The deal includes lowering prices in Medicaid and launching new products with balanced pricing. GSK will offer savings of up to 66% on its inhaled respiratory portfolio and secure a reserve of albuterol for the US. CEO Emma Walmsley emphasizes GSK's commitment to affordable medicine access and respiratory innovation.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments